X4 PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
X4 PHARMACEUTICALS, INC (XFOR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 103.70% for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-08.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2025-08-08
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-06-30 was 103.70%, a 7.46% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-03-31 was 103.90%, a 8.57% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-09-30 was 101.40%, a 7.07% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-06-30 was 96.50%, a 3.32% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 98.30%, a 4.69% increase from fiscal 2023.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 93.90%, a 2.19% decline from fiscal 2022.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 96.00%, a 1.34% decline from fiscal 2021.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2021 was 97.30%, a 2.53% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2025-06-30 | 103.70% 10-Q · filed 2025-08-08 | 103.80% 10-Q · filed 2025-08-08 | ||
| 2025-03-31 | 103.90% 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | 98.30% 10-K · filed 2025-03-26 | |||
| 2024-09-30 | 101.40% 10-Q · filed 2024-11-13 | 97.60% 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | 96.50% 10-Q · filed 2025-08-08 | 96.00% 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | 95.70% 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | 93.90% 10-K · filed 2025-03-26 | |||
| 2023-09-30 | 94.70% 10-Q · filed 2024-11-13 | 93.50% 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | 93.40% 10-Q · filed 2024-08-08 | 92.10% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 90.80% 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | 96.00% 10-K · filed 2025-03-26 | |||
| 2022-09-30 | 95.70% 10-Q · filed 2023-11-09 | 94.80% 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | 95.10% 10-Q · filed 2023-08-10 | 94.60% 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | 94.50% 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | 97.30% 10-K · filed 2024-03-21 | |||
| 2021-09-30 | 95.70% 10-Q · filed 2022-11-03 | 97.60% 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | 97.10% 10-Q · filed 2022-08-04 | 99.30% 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | 101.40% 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 94.90% 10-K · filed 2023-03-21 | |||
| 2020-09-30 | 95.10% 10-Q · filed 2021-11-04 | 94.90% 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | 95.50% 10-Q · filed 2021-08-03 | 94.80% 10-Q · filed 2021-08-03 | ||
| 2020-03-31 | 94.10% 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 88.50% 10-K · filed 2022-03-17 | |||
| 2019-09-30 | 84.50% 10-Q · filed 2020-11-05 | 88.00% 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | 88.00% 10-Q · filed 2020-08-04 | 88.90% 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | 90.60% 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | 86.00% 10-K · filed 2021-03-19 | |||
| 2018-09-30 | 86.70% 10-Q · filed 2019-11-07 | 86.70% 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | 87.40% 10-Q · filed 2019-08-07 | 86.70% 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | 86.00% 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | 77.30% 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |